You are here
Home > the Helsinn Group

Helsinn Group supports Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund

Helsinn Group supports Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund Lugano, Switzerland, June 10, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces that Helsinn is supporting Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund, with a donation of US$100,000. The COVID […]

New Insights on Mechlorethamine/Chlormethine gel presented at 4th World Congress of Cutaneous Lymphomas

New Insights on Mechlorethamine/Chlormethine gel presented at 4th World Congress of Cutaneous Lymphomas Lugano, Switzerland, February 14, 2020 – Helsinn, the Swiss pharmaceutical group focused on building quality cancer care products, today announces that scientific abstracts have been accepted for oral presentation and one abstract for poster presentation at the World Congress of Cutaneous Lymphomas […]

New Insights on Mechlorethamine/Chlormethine gel presented at 4th World Congress of Cutaneous Lymphomas

New Insights on Mechlorethamine/Chlormethine gel presented at 4th World Congress of Cutaneous Lymphomas Lugano, Switzerland, February 14, 2020 – Helsinn, the Swiss pharmaceutical group focused on building quality cancer care products, today announces that scientific abstracts have been accepted for oral presentation and one abstract for poster presentation at the World Congress of Cutaneous Lymphomas […]

Helsinn demonstrates commitment to MF CTCL with multiple scientific sessions at the EORTC Cutaneous Lymphoma Meeting 2019

Helsinn demonstrates commitment to MF CTCL with multiple scientific sessions at the EORTC Cutaneous Lymphoma Meeting 2019 Lugano, Switzerland, September 26, 2019 – Helsinn, the Swiss pharmaceutical group focused on building quality cancer care products, today announces two further abstracts have been accepted for oral presentations at the European Organization for Research and Treatment of […]

Helsinn announces abstract accepted for oral presentation at the EORTC Cutaneous Lymphoma Meeting 2019

Helsinn announces abstract accepted for oral presentation at the EORTC Cutaneous Lymphoma Meeting 2019 Lugano, Switzerland, September 26, 2019 – Helsinn, the Swiss pharmaceutical group focused on building quality cancer care products, today announces an abstract has been accepted for oral presentation at the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma […]

Helsinn and Mundipharma China Pharmaceutical jointly announce NMPA’s approval of the oral formulation of Akynzeo® in China

Helsinn and Mundipharma China Pharmaceutical jointly announce NMPA’s approval of the oral formulation of Akynzeo® in China Lugano, Switzerland, and Beijing, China, September 16, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Mundipharma China Pharmaceutical, the market leader in pain management, today jointly announce that the National Medical […]

Top